Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa trial (NCT06657222). The ...

TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite ...

The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial diseases and builds directly from our Antibody Biopolymer Conjugate ...

Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This press ...

“We are excited to a High DAR Dual-Payload ADC Sutro unveils unique cell-free capabilities Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden ...

CHENGDU, China I January 07, 2025 I The board (the “Board”) of directors (“Directors”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) is ...

YouTuber Zara Dar, who quit her PhD program to join OnlyFans as an adult content creator has revealed that she has been sharing her STEM (Science, technology, engineering, and mathematics ...

YouTuber Zara Dar, after quitting her PhD to join OnlyFans, now uploads her STEM videos to both YouTube and Pornhub, claiming significantly higher earnings from Pornhub. Despite fewer views on the ...

Zara Dar, a former PhD candidate, left academia due to financial uncertainties and now earns over $1 million as a digital content creator. Her educational STEM videos, especially on unconventional ...

YouTuber Zara Dar revealed her shift from a PhD to OnlyFans, highlighting higher ad revenue from Pornhub for her STEM videos. YouTuber Zara Dar, who made headlines overnight after she announced ...

Co., Ltd. (“MediLink”) to use MediLink’s TMALIN ® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.